Search results for "peristaltic pump"

Catch Specac at Pittcon, booth 4141 to learn about all their latest innovations

QIAGEN And Inova Translational Medicine Institute Introduce New Database of Ethnically and Phenotypically Diverse Whole Genome Information

SARS-CoV-2 Spike-E-M Mosaic protein is a recombinant antigen manufactured in E. coli with greater than 95% purity, and containing the Spike (S), Envelope (E) and Membrane (M) immunodominant regions. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

Novel Coronavirus 2019-nCoV (SARS-CoV-2) Spike Glycoprotein (S1) is a recombinant antigen which contains the Spike protein amino acids 1-674. Spike S1 protein is manufactured in HEK293 mammalian cells, ensuring the most authentic post-translational modifications.

Novel Coronavirus 2019-nCoV (SARS-CoV-2) Spike Glycoprotein (S2) is a recombinant antigen which contains the Spike S2 protein, amino acids 685-1211. Spike S2 is manufactured in mammalian HEK293 cells to ensure the most authentic post-translational modifications.

With abundant data on plants, large animals and their activity, and carbon soil levels in the Amazon, Stanford research suggests that large animal diversity influences carbon stocks and contributes to climate change mitigation

SARS-CoV-2 Spike Glycoprotein (S2) is a recombinant antigen which contains the Spike protein amino acids 685-1211 of subunit 2. Spike S2 protein is manufactured to high yield and purity using the Native Antigens baculovirus-insect cell platform. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

Chromatography experts share how the latest 2D-LC technology can benefit your pharmaceutical, food, or polymer analysis applications and more

Read this exclusive interview with Louise Kenny, one of the founding directors of the INFANT Centre, to discover how they are using mass spectrometry to research preeclampsia and pre-term birth

Find out how the Department of Laboratory Medicine at La Paz University Hospital is utilizing the Siemens DCA Vantage to improve diabetes monitoring and patient care

AEOL 10150 is currently the only drug being developed by BARDA to address the delayed effects of radiation exposure